Abstract
Patient: Male, 76-year-old Final Diagnosis: Left atrial appendage thrombus despite optimal anticoagulation Symptoms: Palpitations Medication: — Clinical Procedure: Cryoballoon-based ablation • percutaneous left atrial appendage closure • transesopha-geal echocardiogram Specialty: Cardiology Objective: Background: Case Report: Conclusions: Unusual clinical course Despite use of optimal oral anticoagulation regimens, left atrial appendage (LAA) thrombus may develop and persist in patients with atrial fibrillation (AF). The therapeutic options in this population are limited. Percutaneous LAA closure (LAAC) is performed to reduce thrombus formation and the risk of thromboembolism. However, this approach is prohibited in patients with LAA thrombus. We report the case of a 76-year-old man with AF and persistent LAA thrombus who underwent percutaneous LAAC with the LAmbre device protected by the SENTINEL Cerebral Protection System (CPS). A 76-year-old man with history of persistent AF treated with pulmonary veins and LAA isolation developed LAA thrombus resistant to different anticoagulation therapies, including apixaban and Phenprocoumon, with a target international normalized ratio (INR) of 3-3,5. Repeated follow-up transesophageal echocardiography showed a persistent LAA thrombus despite optimal INR values. Thus, we performed a percutaneous LAAC using a double-umbrella-designed appendage occluder and a CPS to minimize the risk of intraprocedural cerebral embolization. The procedure was guided by transesophageal echocardiography and fluoroscopy. No signs of systemic thromboembolism were noted, and the CPS filters showed no evidence of thrombotic material. This report shows that the use of a CPS during percutaneous LAAC may reduce the risk of procedural cerebral embolization and could be used as an alternative therapy for patients with contraindication or lack of effec-tiveness of oral anticoagulation.
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | e937063 |
| Zeitschrift | American Journal of Case Reports |
| Jahrgang | 23 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 2022 |
Fördermittel
Roland Richard Tilz, e-mail: [email protected] None declared CHH received travel grants and research grants from Boston Scientific, Biosense Webster, and Cardiofocus, and Speaker’s Honoraria from Boston Scientific, Biosense Webster, and Cardiofocus. RRT is a consultant of Boston Scientific, Biotronik and Biosense Webster and received Speaker’s Honoraria from Biosense Webster, Medtronic, Boston Scientific, and Abbot Medical. All other authors have no relevant disclosures
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Zentren: Universitäres Herzzentrum Lübeck (UHZL)
DFG-Fachsystematik
- 2.22-12 Kardiologie, Angiologie
Fingerprint
Untersuchen Sie die Forschungsthemen von „Percutaneous Left Atrial Appendage Closure with the LAmbre Device Protected by a Cerebral Protection System in a 76-Year-Old Man with Persistent Left Atrial Appendage Thrombus“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver